SLC5A2 and metabolic dysfunction-associated steatohepatitis: Hosokawa et al. have shown that ipragliflozin, another SGLT2 inhibitor, can reduce ectopic lipid accumulation in tubular cells in non-alcoholic steatohepatitis (NASH)-model mice [33].